Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of REGN3470-3471-3479 in Healthy Adults
NCT02777151Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REGN-EB3 in Ebola virus disease (EVD) (4 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at Day 169. Started May 2016; status: completed.
02
Drugs
REGN-EB3
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02777151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777151.